478 results on '"Boddy, Alan V"'
Search Results
2. Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance
3. Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib
4. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma
5. Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John’s Wort
6. Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia
7. Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence
8. Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect
9. Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide
10. The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients
11. A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours
12. A Retinol Isotope Dilution Equation Predicts Both Group and Individual Total Body Vitamin A Stores in Adults Based on Data from an Early Postdosing Blood Sample
13. Plasma Retinol Kinetics and β-Carotene Bioefficacy Are Quantified by Model-Based Compartmental Analysis in Healthy Young Adults with Low Vitamin A Stores
14. Imagestream detection and characterisation of circulating tumour cells – A liquid biopsy for hepatocellular carcinoma?
15. Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma
16. Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer
17. Supplementary Figures 1 and 2 from Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System
18. Data from Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System
19. Metabolism (Non-CYP Enzymes)
20. Supplementary Table 1 from A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study
21. Supplementary Figure 1 from Adaptive Dosing Approaches to the Individualization of 13-Cis-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma
22. Supplementary Data from Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma
23. Supplementary Figure 1 from A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study
24. Supplementary Figure Legend from Adaptive Dosing Approaches to the Individualization of 13-Cis-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma
25. Supplementary Figure 2 from Adaptive Dosing Approaches to the Individualization of 13-Cis-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma
26. An LC/MS/MS method for stable isotope dilution studies of β-carotene bioavailability, bioconversion, and vitamin A status in humans
27. Towards a Model-Based Dose Recommendation for Doxorubicin in Children
28. Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a “European Pediatric Oncology Off-patents Medicines Consortium” trial
29. Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours
30. Metabolism (Non-CYP Enzymes)
31. Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo
32. Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer
33. Chemotherapy in newborns and preterm babies
34. Therapy-induced carboplatin–DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues
35. Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
36. Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy
37. Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS‐CoV‐2 Infection: A Case Study With Imatinib
38. Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis
39. Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil
40. Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer
41. Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer
42. Role of UDP-Glucuronosyltransferase Isoforms in 13-cis Retinoic Acid Metabolism in Humans
43. Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate
44. High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers
45. Physiologically‐based pharmacokinetic model predictions of inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens
46. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years
47. Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients
48. Population Pharmacokinetic Investigation of Actinomycin-D in Children and Young Adults
49. An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed
50. Metabolism (Non-CYP Enzymes)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.